Table 1.
Patient characteristics (n = 188).
| Characteristics | n | % |
|---|---|---|
| Age, years (median, range) | 65 (26–80) | |
| Gender | ||
| Female | 70 | 37 |
| Male | 118 | 63 |
| Karnofsky (n = 165) | ||
| ≥80 | 135 | 82 |
| <80 | 30 | 18 |
| HCT-CI (n = 155) | ||
| Low | 29 | 18 |
| Intermediate | 55 | 35 |
| High | 74 | 47 |
| AML subtype (n = 186) | ||
| AML-MRC | 131 | 70 |
| t-AML | 53 | 29 |
| Othera | 2 | 1 |
| 2017 ELN genetic risk (n = 179) | ||
| Favorable | 12 | 7 |
| Intermediate | 59 | 33 |
| Adverse | 108 | 60 |
| Karyotype (n = 179) | ||
| Normal | 63 | 35 |
| Abnormal | 116 | 65 |
| Complex | 44 | 25 |
| Non-complex | 72 | 40 |
| Molecular genetics | ||
| NPM1/n.d. | 18/11 | 10/6 |
| FLT3-ITD/n.d. | 13/13 | 7/7 |
| ASXL1/n.d. | 31/24 | 16/13 |
| TP53/n.d. | 14/26 | 7/14 |
| RUNX1/n.d. | 24/20 | 13/11 |
| BM blast count at diagnosis (median, range) | 38 (7–99) | |
| PB blast count at diagnosis (median, range) | 10 (0–92) | |
| WBC at diagnosis, ×103/µl (median, range) | 3.8 (0.6–330) | |
| No treatment prior CPX | 169 | 90 |
| Pretreatment with HMA | 19 | 10 |
AML acute myeloid leukemia, AML-MRC AML with myelodysplasia-related changes, BM bone marrow, ELN European Leukemia Net, HCT-CI hematopoietic cell transplantation-specific comorbidity index, HMA hypomethylating agents, n.d. not done, n number, PB peripheral blood, t-AML therapy-related AML, WBC white blood cells.
Numbers in parentheses display patients with available information.
aSecondary AML evolving from systemic mastocytosis (n = 1) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) with antecedent history of chronic myelomonocytic leukemia (CMML) (n = 1).